“…31 In addition to its role as a transactivator of many genes, [33][34][35] C/EBP (originally cloned as LAP, NF-IL6, and IL-6DBP) 33,34,36 arrests the progression of the cell cycle from G1 to S-phase in hepatoma cells 37 and mediates the proliferative effects of oxidative stress and TGF-␣ in colonic cancer cells 38 and primary mouse hepatocytes. 9 Lipopolysaccharide (LPS)-stimulated factors appear to regulate the selection of AUG start sites for both activation and repression of messenger RNA (mRNA) translation from the 5 C/EBP␣ and 3 C/EBP AUG codons. 39 The liver inhibitor protein (LIP), an alternative, shorter translation product initiated at the third AUG codon of the C/EBP mRNA, behaves as a C/EBP transcription antagonist since it shares with C/EBP the DNA binding and leucine zipper domains but lacks the transactivation domain.…”